Literature DB >> 29296763

A case of lenalidomide-dependent myelodysplastic syndrome.

Ira J Miller1, Wei-Tong Hsu1, James Weisberger2, Parameswaran Venugopal3.   

Abstract

A man with cytopenias, dysplasia, excess blasts, P53 and RUNX1 mutations, and ring chromosome 7 recovered after stopping lenalidomide.

Entities:  

Year:  2017        PMID： 29296763      PMCID： PMC5728548          DOI： 10.1182/bloodadvances.2017006114

Source DB:  PubMed          Journal:  Blood Adv        ISSN： 2473-9529


  13 in total

1.  Periodic morphologic, cytogenetic and clonality evaluation after autologous peripheral blood progenitor cell transplantation in patients with lymphoproliferative malignancies.

Authors:  Luca Laurenti; Patrizia Chiusolo; Maria Grazia Garzia; Gina Zini; Federica Sorà; Nicola Piccirillo; Paola Piccioni; Marcella Zollino; Giuseppe Leone; Simona Sica
Journal:  Haematologica       Date:  2002-01       Impact factor: 9.941

2.  Multiple myeloma cells' capacity to decompose H2O2 determines lenalidomide sensitivity.

Authors:  Sinto Sebastian; Yuan X Zhu; Esteban Braggio; Chang-Xin Shi; Sonali C Panchabhai; Scott A Van Wier; Greg J Ahmann; Marta Chesi; P Leif Bergsagel; A Keith Stewart; Rafael Fonseca
Journal:  Blood       Date:  2016-12-27       Impact factor: 22.113

3.  A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma.

Authors:  Paul G Richardson; Emily Blood; Constantine S Mitsiades; Sundar Jagannath; Steven R Zeldenrust; Melissa Alsina; Robert L Schlossman; S Vincent Rajkumar; K Raman Desikan; Teru Hideshima; Nikhil C Munshi; Kathleen Kelly-Colson; Deborah Doss; Mary L McKenney; Svetlana Gorelik; Diane Warren; Andrea Freeman; Rebecca Rich; Anfang Wu; Marta Olesnyckyj; Kenton Wride; William S Dalton; Jerome Zeldis; Robert Knight; Edie Weller; Kenneth C Anderson
Journal:  Blood       Date:  2006-07-13       Impact factor: 22.113

4.  Dexamethasone and lenalidomide have distinct functional effects on erythropoiesis.

Authors:  Anupama Narla; Shilpee Dutt; J Randall McAuley; Fatima Al-Shahrour; Slater Hurst; Marie McConkey; Donna Neuberg; Benjamin L Ebert
Journal:  Blood       Date:  2011-04-28       Impact factor: 22.113

5.  Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells.

Authors:  Jan Krönke; Namrata D Udeshi; Anupama Narla; Peter Grauman; Slater N Hurst; Marie McConkey; Tanya Svinkina; Dirk Heckl; Eamon Comer; Xiaoyu Li; Christie Ciarlo; Emily Hartman; Nikhil Munshi; Monica Schenone; Stuart L Schreiber; Steven A Carr; Benjamin L Ebert
Journal:  Science       Date:  2013-11-29       Impact factor: 47.728

Review 6.  Therapy-related myeloid neoplasms.

Authors:  Arnold Ganser; Michael Heuser
Journal:  Curr Opin Hematol       Date:  2017-03       Impact factor: 3.284

7.  Reciprocal DNA topoisomerase II cleavage events at 5'-TATTA-3' sequences in MLL and AF-9 create homologous single-stranded overhangs that anneal to form der(11) and der(9) genomic breakpoint junctions in treatment-related AML without further processing.

Authors:  Ryan J Whitmarsh; Charles Saginario; Ya Zhuo; Eva Hilgenfeld; Eric F Rappaport; Maureen D Megonigal; Martin Carroll; Mingli Liu; Neil Osheroff; Nai-Kong V Cheung; Diana J Slater; Thomas Ried; Turid Knutsen; Ian A Blair; Carolyn A Felix
Journal:  Oncogene       Date:  2003-11-20       Impact factor: 9.867

Review 8.  Maintenance Therapy With Immunomodulatory Drugs in Multiple Myeloma: A Meta-Analysis and Systematic Review.

Authors:  Yucai Wang; Fang Yang; Yan Shen; Wenwen Zhang; Jacqueline Wang; Victor T Chang; Borje S Andersson; Muzaffar H Qazilbash; Richard E Champlin; James R Berenson; Xiaoxiang Guan; Michael L Wang
Journal:  J Natl Cancer Inst       Date:  2015-11-18       Impact factor: 13.506

9.  The myeloma drug lenalidomide promotes the cereblon-dependent destruction of Ikaros proteins.

Authors:  Gang Lu; Richard E Middleton; Huahang Sun; MarkVic Naniong; Christopher J Ott; Constantine S Mitsiades; Kwok-Kin Wong; James E Bradner; William G Kaelin
Journal:  Science       Date:  2013-11-29       Impact factor: 47.728

10.  Role of TP53 mutations in the origin and evolution of therapy-related acute myeloid leukaemia.

Authors:  Terrence N Wong; Giridharan Ramsingh; Andrew L Young; Christopher A Miller; Waseem Touma; John S Welch; Tamara L Lamprecht; Dong Shen; Jasreet Hundal; Robert S Fulton; Sharon Heath; Jack D Baty; Jeffery M Klco; Li Ding; Elaine R Mardis; Peter Westervelt; John F DiPersio; Matthew J Walter; Timothy A Graubert; Timothy J Ley; Todd Druley; Daniel C Link; Richard K Wilson
Journal:  Nature       Date:  2014-12-08       Impact factor: 49.962
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.